Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05979311
Other study ID # 219816
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date December 29, 2023
Est. completion date August 24, 2026

Study information

Verified date December 2023
Source ViiV Healthcare
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare safety, efficacy, participant reported outcomes and implementation outcomes of a fixed dose combination (FDC) of a two-drug regimen dolutegravir (DTG) plus lamivudine (3TC) and a three-drug regimen FDC of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) in HIV-1 infected adult participants who have not previously received antiretroviral therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 412
Est. completion date August 24, 2026
Est. primary completion date September 22, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants with age >=18 years (or older, if required by local regulations) at the time of obtaining informed consent. - An individual participant is eligible to participate if they are not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at Screening and a negative urine hCG test at Enrollment) and not lactating. - Antiretroviral-naïve (no prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) person living with HIV. - Participant (or participant's legally acceptable representative [LAR]) is capable of giving written informed consent. - Eligible participants or their LAR must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrollment of participants who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures. - Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category. Exclusion Criteria: - Individuals who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study. - Any evidence of a current Centers for Disease Control and Prevention (CDC) Stage 3 disease; with the exception of cutaneous Kaposi's sarcoma not requiring systemic therapy, and CD4+ count <200 cells per cubic millimeter (neither is exclusionary). - History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates study participation. - Ongoing or clinically relevant pancreatitis. - Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the Investigator and the Medical Monitor for inclusion of the participant prior to enrollment. - Participants with severe hepatic impairment (Class C) as determined by Child-Pugh classification. - Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment). - History of liver cirrhosis with or without hepatitis viral co-infection. - Alanine aminotransferase (ALT) >=5 times the upper limit of normal (ULN) or ALT >=3*ULN and bilirubin >=1.5*ULN (with >35% direct bilirubin). - Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrollment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrollment. - Participants who, in the investigator's judgment, pose a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk. - Signs and symptoms which, in the opinion of the Investigator, are suggestive of active Coronavirus disease 2019 (COVID-19) (example fever, cough) infection within 14 days prior to enrollment. - Evidence of Hepatitis B virus (HBV) infection based on the results of central lab testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis B surface antibody (HBsAb) and HBV Deoxyribonucleic Acid (DNA) as follows: a. Participants positive for HBsAg are excluded; b. Participants negative for HBsAb and negative for HBsAg but positive for hepatitis B core antibody (HBcAb) may be excluded based on the following consideration: i. Exclude if HBV DNA is detected [either <Lower Limit of Quantification (LLoQ), >Upper Limit of Quantification (ULoQ) OR numerical value (i.e., between LLoQ and ULoQ)] ii. Not excluded if HBV DNA is negative, not detected - Participants with Hepatitis C virus (HCV) co-infection at Screening are eligible only if: i. liver enzymes meet entry criteria; and ii. HCV disease is not anticipated to require on-study treatment with any agent(s) that have potential adverse drug-drug interactions (DDIs) with the study interventions; and iii. HCV disease has undergone appropriate work-up and is not advanced and will not require treatment prior to the primary endpoint or later visit. Additional information on participants with HCV co-infection at screening should include results from any liver biopsy, Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment. iv. In the event that recent biopsy or imaging data is not available or inconclusive, the Fib-4 score will be used to verify eligibility 1. Fib-4 score >3.25 is exclusionary; 2. Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 score Formula: (Age * Aspartate aminotransferase [AST]) / (Platelets * (square root of ALT) - Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded. Participants with a false positive RPR (with negative treponemal test) or serofast RPR result (persistence of a reactive nontreponemal syphilis test despite history of adequate therapy and no evidence of re-exposure) may enroll after consultation with the Medical Monitor. Participants who completed treatment at least 7 days prior to Screening are eligible. - Presence of any major resistance-associated mutations as defined by the International Antiviral Society-United States of America (IAS-USA) resistance guidelines to DTG, 3TC, BIC, FTC or TAF in the Screening result. - Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to first dose of study treatment. - Treatment with any of the following agents within 28 days of Screening: i. radiation therapy; ii. cytotoxic chemotherapeutic agents; iii. tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid, INH); iv. immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons. - Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening. - Treatment with any agent with documented activity against HIV-1 in vitro within 28 days of first dose of study treatment. Treatment withacyclovir/valacyclovir is permitted. - Participants receiving any protocol-defined prohibited medication and who are unwilling or unable to switch to an alternate medication. - Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities. - Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in an interventional clinical trial. - Participant has estimated creatine clearance <30 milliliter per minute (mL/min) per 1.73 square meter using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R) method. - Participants known or suspected to have acquired HIV-1 concurrent with use of Pre-exposure prophylaxis (PrEP) or Post-exposure prophylaxis (PEP) must be discussed with the Medical Monitor prior to enrollment. - Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication. - Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant. - Participant is currently participating in, or anticipates being selected for, any other interventional study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dolutegravir
Dolutegravir will be administered once daily.
Lamivudine
Lamivudine will be administered once daily.
Bictegravir
Bictegravir will be administered once daily.
Emtricitabine
Emtricitabine will be administered once daily.
Tenofovir alafenamide
Tenofovir alafenamide will be administered once daily.

Locations

Country Name City State
Argentina GSK Investigational Site Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina GSK Investigational Site Cordoba Córdova
Belgium GSK Investigational Site Antwerpen
Belgium GSK Investigational Site Brussels
Belgium GSK Investigational Site Gent
Denmark GSK Investigational Site Hvidovre
France GSK Investigational Site Bordeaux
France GSK Investigational Site Bordeaux
France GSK Investigational Site Montpellier
France GSK Investigational Site Nice Cedex 3
France GSK Investigational Site Nîmes
France GSK Investigational Site Paris
France GSK Investigational Site Paris
France GSK Investigational Site Paris
France GSK Investigational Site Paris cedex 20
France GSK Investigational Site Toulouse cedex 9
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Frankfurt Hessen
Germany GSK Investigational Site Hamburg
Germany GSK Investigational Site Koeln Nordrhein-Westfalen
Germany GSK Investigational Site München
Greece GSK Investigational Site Athens
Greece GSK Investigational Site Athens
Greece GSK Investigational Site Thessaloniki
Ireland GSK Investigational Site Dublin
Ireland GSK Investigational Site Dublin
Israel GSK Investigational Site Haifa
Israel GSK Investigational Site Ramat Gan
Israel GSK Investigational Site Rehovot
Israel GSK Investigational Site Tel Aviv
Italy GSK Investigational Site Bari Puglia
Italy GSK Investigational Site Bergamo Lombardia
Italy GSK Investigational Site Padova
Italy GSK Investigational Site Pavia
Italy GSK Investigational Site Sassari Sardegna
Japan GSK Investigational Site Aichi
Japan GSK Investigational Site Osaka
Japan GSK Investigational Site Tokyo
Japan GSK Investigational Site Tokyo
Mexico GSK Investigational Site García Gineres Mérida
Mexico GSK Investigational Site Zapopan Jalisco
Poland GSK Investigational Site Bydgoszcz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Wroclaw
Portugal GSK Investigational Site Aveiro
Portugal GSK Investigational Site Porto
Spain GSK Investigational Site Badalona
Spain GSK Investigational Site Barcelona
Spain GSK Investigational Site Elche
Spain GSK Investigational Site las Palmas de Gran Canaria Canary Islands
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Marbella
Spain GSK Investigational Site Palma de Mallorca
Spain GSK Investigational Site Palma de Mallorca
Spain GSK Investigational Site Valencia
Sweden GSK Investigational Site Stockholm
Switzerland GSK Investigational Site Basel
Switzerland GSK Investigational Site Zürich
United Kingdom GSK Investigational Site Glasgow
United Kingdom GSK Investigational Site London
United Kingdom GSK Investigational Site London
United Kingdom GSK Investigational Site London
United Kingdom GSK Investigational Site London

Sponsors (1)

Lead Sponsor Collaborator
ViiV Healthcare

Countries where clinical trial is conducted

Argentina,  Belgium,  Denmark,  France,  Germany,  Greece,  Ireland,  Israel,  Italy,  Japan,  Mexico,  Poland,  Portugal,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants with plasma HIV- Ribonucleic acid (RNA) less than (<)50 copies per milliliter (c/mL) as per snapshot algorithm at Week 48 Week 48
Secondary Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Weeks 24 and 96 Weeks 24 and 96
Secondary Percentage of participants with HIV-RNA greater than or equal to (>=)50 c/mL as per snapshot algorithm at Weeks 24, 48, and 96 Weeks 24, 48 and 96
Secondary Change from Baseline in HIV-1 RNA at Weeks 24, 48 and 96 Baseline (Day 1) and Weeks 24, 48 and 96
Secondary Change from Baseline in Cluster of differentiation 4 positive (CD4+) cell count at Weeks 24, 48 and 96 Baseline (Day 1) and Weeks 24, 48 and 96
Secondary Change from Baseline in CD4/Cluster of differentiation 8 (CD8) at Weeks 24, 48 and 96 Baseline (Day 1) and Weeks 24, 48 and 96
Secondary Number of Participants With HIV-1 Disease Progression Weeks 24, 48 and 96
Secondary Time to virologic suppression (HIV-1 RNA <50 c/mL) from Baseline Baseline (Day 1) and Up to Week 96
Secondary Number of participants with confirmed virologic withdrawal (CVW) Up to Week 96
Secondary Number of Participants with treatment-emergent resistance Up to week 96
Secondary Change from Baseline in Renal Biomarkers- estimated glomerular filtration rate at Weeks 48 and 96 Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in Renal Biomarkers- urinary protein/creatinine at Weeks 48 and 96 Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in renal biomarker- Serum Cystatin C at Weeks 48 and 96 (Milligrams per liter) Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in renal biomarker- Serum Retinol Binding Protein (RBP) at Weeks 48 and 96 (Milligrams per deciliter) Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in renal biomarker- Serum Beta-2 Microglobulin (B2M) at Weeks 48 and 96 (Micrograms per milliliter) Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in bone biomarkers- Serum Bone Specific Alkaline Phosphatase, Serum Procollagen type 1 N- Propeptide, Serum Type I Collagen C-Telopeptides and Serum Osteocalcin at Weeks 48 and 96 (Micrograms per Liter) Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in bone biomarkers- Serum Vitamin D at Weeks 48 and 96 (Nanomoles per Liter) Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline (Week 4) in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction status Questionnaire (HIVTSQs) at Weeks 12, 24, 48 and 96 (Scores on a scale) The HIVTSQ status version (HIVTSQs) is assessing participants' satisfaction with their current treatment with a Total score ranging from 0 to 60. Higher scores indicate a greater level of satisfaction with HIV treatment. Baseline is defined as measurement value at Week 4. Baseline (Week 4) and Weeks 12, 24, 48 and 96
Secondary Change from Baseline (Week 4) in Individual Item Scores Using HIVTSQs at Weeks12, 24, 48 and 96 (Scores on a scale) Individual items scores range from 0 to 6 (0=very dissatisfied, 6=very satisfied). Baseline is defined as measurement value at Week 4. Baseline (Week 4) and Weeks 12, 24, 48 and 96
Secondary Change from Baseline (Week 4) in Domains Scores Using HIVTSQs at Weeks 12, 24, 48 and 96 (Scores on a scale) There are two domain scores of General Satisfaction/Clinical and Lifestyle/Ease subscales; each comprised of 5 items with possible scores of 0 to 30. The higher the score, the greater the satisfaction within the subscale. Baseline is defined as measurement value at Week 4. Baseline (Week 4) and Weeks 12, 24, 48 and 96
Secondary Change from Baseline in bothersome symptoms using the Symptom Distress Module at Weeks 4, 12, 24, 48 and 96 (Score on a scale) The Symptom Distress Module (SDM) is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom bother score is based on the score for each symptom present ranging from 1 (it does not bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). Baseline (Day 1) and Weeks 4, 12, 24, 48 and 96
Secondary Absolute values for waist and hip circumference (Centimeters) Up to Week 96
Secondary Absolute values for waist to hip ratio and waist to height ratio (Ratio) Up to Week 96
Secondary Absolute values for Body weight (Kilogram) Up to Week 96
Secondary Absolute values for systolic and diastolic blood pressure (millimeters of mercury) Up to Week 96
Secondary Change from Baseline in Body Mass Index (kilogram per square meter) Baseline (Day 1) and Up to Week 96
Secondary Change from Baseline in body weight greater than (>) 5 percentage (%) at Weeks 24, 48 and 96 Baseline (Day 1) and Weeks 24, 48 and 96
Secondary Change from Baseline in total and regional (trunk and extremities) fat assessed by Dual-energy X-ray absorptiometry (DXA) at Weeks 48 and 96 Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in total and regional (trunk and extremities) fat-free mass assessed by DXA Weeks 48 and 96 Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in lumbar and hip bone mineral density (BMD) assessed by DXA at Weeks 48 and 96 Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in trabecular bone score (TBS) assessed by DXA at Weeks 48 and 96 Trabecular bone score (TBS) is a lumbar spine dual-energy absorptiometry texture index, which provides information on microarchitecture skeletal quality partially independent of BMD. Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in fasting glucose (Millimoles per Liter) Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in insulin (Microunits per millilliter) Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 48 and Week 96 Baseline (Day 1), Week 48 and Week 96
Secondary Change from Baseline in Hemoglobin A1c [HbA1c] at Week 48 and Week 96 (Percentage of HbA1c) Baseline (Day 1), Week 48 and Week 96
Secondary Change from Baseline in plasma lipids (total, high-density lipoprotein [HDL], and low-density lipoprotein [LDL] cholesterol, triglycerides) (Millimoles per Liter) at Week 48 and Week 96 Baseline (Day 1), Week 48 and Week 96
Secondary Change from Baseline in QDiabetes Score at Week 48 and Week 96 (Scores on a scale) QDiabetes score defines the risk (percentage) of developing type 2 Diabetes in the next ten years. The score ranges from 0-100. Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in Fibrosis 4 (FIB-4) Score at Week 48 and Week 96 (Scores on a scale) A value of FIB-4 scores below 1.30 is considered as low risk for advanced fibrosis; value of FIB-4 over 2.67 is considered as high risk for advanced fibrosis; and FIB-4 values between 1.30 and 2.67 are considered as intermediate risk of advanced fibrosis. Baseline (Day 1), Weeks 48 and 96
Secondary Number of participants with metabolic syndrome at Weeks 48 and 96 Weeks 48 and 96
Secondary Change from Baseline in Framingham cardiovascular risk scores at Weeks 48 and 96 (Scores on a scale) Coronary heart disease (CHD) risk at 10 years in percent (%) can be calculated with the help of the Framingham Risk Score. Individuals with low risk have 10% or less CHD risk at 10 years, with intermediate risk 10-20%, and with high risk 20% or more. Baseline (Day 1), Weeks 48 and 96
Secondary Change from Baseline in Data collection on Adverse events of anti-HIV Drugs (DAD) cardiovascular risk scores at Weeks 48 and 96 (Scores on a scale) Coronary heart disease (CHD) risk at 5 years in percent can be calculated with the help of the DAD Risk Score. The 5-year risk of CHD is classified as low (<1%), moderate (1 to 5%), high (5 to 10%), or very high (>10%). Baseline (Day 1), Weeks 48 and 96
Secondary Changes from Baseline in Systolic and diastolic blood pressure at Weeks 48 and 96 millimeters of mercury (mmHg) Baseline (Day 1), Weeks 48 and 96
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2